Pyrazinamide (PZA) testing is suspended due to issues with the manufacturer’s kit. ARUP will continue testing the other first-line drugs: rifampin, isoniazid, and ethambutol. If PZA susceptibility testing is required during this test delay, contact your local public health laboratory or the CDC for pncA gene testing for PZA resistance mutations.

0060217
print

Antimicrobial Susceptibility, AFB/Mycobacteria

MA AFB
Example Reports
Standard

Ordering Recommendation

Identify susceptibility of clinically significant isolates of M. tuberculosis complex (MTBC), M. kansasii, M. avium-intracellulare complex, M. fortuitum complex, M. abscessus complex, M. chelonae, M. immunogenum, and any isolate from a significant source.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Actively growing isolate in pure culture.

Specimen Preparation

Transport sealed container with pure culture on solid or liquid media. Place each specimen in an individually sealed bag.

Storage/Transport Temperature

Room temperature. If culture is suspected of being a microorganism identified on the IATA list as an infectious substance affecting humans, submit specimen according to Infectious Substance, Category A, shipping guidelines.

Unacceptable Conditions

Mixed cultures or nonviable organisms. Organisms submitted on an agar plate.

Remarks
Stability

Ambient: 2 weeks; Refrigerated: 2 weeks; Frozen: 2 weeks

Methodology

Broth Macrodilution/Broth Microdilution

Performed

Sun-Sat

Reported

Varies

Reference Interval

Available Separately
 Test Name
 Methodology
 Reference Interval/Drugs Tested
 CPT Code
0060347 Antimicrobial Susceptibility - AFB/Mycobacterium tuberculosis Primary Panel MGIT960 The interpretation provided is based on results for the following drugs at the stated concentrations:

Drugs tested: Ethambutol: 5.0 µg/mL; Isoniazid: 0.1 µg/mL (0.4 µg/mL if resistant to 0.1 µg/mL); Pyrazinamide: 100 µg/mL; Rifampin: 1.0 µg/mL.

This procedure screens isolates of M. tuberculosis complex for drug resistance. The procedure does not use serial dilutions to provide quantitative MIC values. Single critical concentrations for each antimycobacterial agent used have been defined by the United States Public Health Service.		 87188 x4
Antimicrobial Susceptibility - AFB/Mycobacterium tuberculosis Secondary Panel Agar proportion
and Broth dilution		 Effective February 21, 2012

Note: If M. tuberculosis isolate is resistant to rifampin or any two primary drugs, a secondary panel will be performed as a send-out test. The interpretation provided is based on testing for the following drugs at the stated concentrations:

Drugs tested: Amikacin: 6 µg/mL; capreomycin: 10 µg/mL; cycloserine: 60 µg/mL; ethionamide: 10 µg/mL; kanamycin: 6 µg/mL; PAS: 8 µg/mL; streptomycin at a low level (2.0 µg/mL) and a high level (4.0 µg/mL). Levofloxacin and moxifloxacin are tested at 2, 4 and 8 µg/mL		 87190 x6, 87188 x3
Antimicrobial Susceptibility - AFB/Mycobacteria Broth Microdilution See organism-specific panels below. 87186
Mycobacterium avium-intracellularae Complex Broth Microdilution Effective April/1/2022

Drugs tested: Amikacin, clarithromycin, linezolid, moxifloxacin.

Clarithromycin results predict azithromycin. Because MIC results do not predict clinical response and may be misleading, rifampin, rifabutin, and ethambutol MICs are not tested.		 87186
Rapid Growing Mycobacteria Broth Microdilution Effective April 1, 2022

Drugs tested: Amikacin, cefoxitin, ciprofloxacin, clarithromycin, doxycycline, imipenem, linezolid, moxifloxacin, tigecycline, tobramycin (M. chelonae only), and trimethoprim/sulfamethoxazole (TMP/SXT). Extended 14-day incubation is performed on isolates initially susceptible to clarithromycin to detect Erm(41)-dependent inducible macrolide resistance except Mycobacterium species with a nonfuctional Erm(41) gene.		 87186
Other Slowly-Growing
Non-tuberculosis Mycobacteria 
(NTM)		 Broth Microdilution Effective April 1, 2022

Drugs tested: Amikacin, ciprofloxacin, clarithromycin, doxycycline, linezolid, moxifloxacin, rifabutin, rifampin, streptomycin and trimethoprim/sulfamethoxazole (TMP/SXT). Selective reporting by organism.

CLSI recommends that isolates of M. kansasii be tested against rifampin and clarithromycin only. Rifampin-susceptible isolates are also susceptible to rifabutin. If the isolate is rifampin-resistant, the following secondary drugs will also be reported: Amikacin, ciprofloxacin, linezolid, moxifloxacin, rifabutin, streptomycin and trimethoprim-sulfamethoxazole.

M. marinum isolates are tested against amikacin, ciprofloxacin, clarithromycin, doxycycline, moxifloxacin, rifabutin, rifampin, and trimethoprim-sulfamethoxazole.

Slowly-growing NTM other than M. kansasii and M. marinum are tested against amikacin, ciprofloxacin, clarithromycin, linezolid, moxifloxacin, rifabutin, rifampin, streptomycin, and trimethoprim-sulfamethoxazole.		 87186

Interpretive Data



Compliance Category

Laboratory Developed Test (LDT)

Note

AFB susceptibility testing is billed at the panel level. Charges will vary based on organism identified. An additional handling fee will be billed for all organisms submitted that are not in pure culture as indicated in the specimen requirements.

If species identification is not provided or if incorrect identification is provided, identification will be performed at ARUP. Additional charges apply.

M. tuberculosis complex isolates mono-resistant to Pyrazinamide (PZA) will be further identified to species by PCR at an additional charge.

An additional charge will be added for drug requests that are not tested at ARUP and require sendout.

Hotline History

N/A

CPT Codes

CPT codes vary based on method

Are you an ARUP Client? Click here for your pricing.

Components

Component Test Code* Component Chart Name LOINC
0060217 Susceptibility, Mycobacteria 29579-0
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Slow-Growing Mycobacterium species
  • Doxycycline susceptibility
  • Levofloxacin susceptibility
  • AFB Susceptibility Panel
  • Capreomycin susceptibility
  • Cefepime susceptibility
  • Cefoxitin susceptibility
  • Ceftriaxone susceptibility
  • Linezolid susceptibility
  • Minocycline susceptibility
  • Moxifloxacin susceptibility
  • Mycobacterium
  • Rapidly-Growing Mycobacterium species
  • RGM
  • Streptomycin susceptibility
  • Rifabutin susceptibility
  • Clarithromycin susceptibility
  • Cycloserine susceptibility
  • Rifampin susceptibility
  • SGM
  • tobramycin (M. chelonae only) susceptibility
  • Trimethoprim/sulfamethoxazole susceptibility
  • Ciprofloxacin susceptibility
  • Amikacin susceptibility
  • Amoxicillin/clavulanic acid susceptibility
  • Mycobacterium tuberculosis susceptibility testing
  • Imipenem susceptibility
  • PAS susceptibility
  • Isoniazid susceptibility
  • Kanamycin susceptibility
  • Pyrazinamide susceptibility
  • Acid Fast Bacilli
  • Tigecycline susceptibility
  • TMP/SXT susceptibility
  • Ethambutol susceptibility
  • Ethionamide susceptibility
Antimicrobial Susceptibility, AFB/Mycobacteria